Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917939 | 0.90 | AR (0.46) | ARPGR | |
| SCHEMBL3919568 | 0.90 | AR (0.48) | ARPGR | |
| SCHEMBL3925330 | 0.86 | AR (0.43) | ARPGR | |
| SCHEMBL3917254 | 0.86 | AR (0.49) | ARPGR | |
| SCHEMBL4203510 | 0.85 | AR (0.48) | ARPGR | |
| SCHEMBL3914797 | 0.85 | AR (0.43) | ARPGR | |
| SCHEMBL3925540 | 0.84 | AR (0.52) | ARPGR | |
| SCHEMBL3917262 | 0.82 | AR (0.53) | ARPGR | |
| SCHEMBL4207249 | 0.80 | AR (0.44) | ARPGR | |
| SCHEMBL3915101 | 0.79 | AR (0.49) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576128-B2 | Androgen receptor modulators | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1716110-A1 | ANDROGEN RECEPTOR MODULATORS | Warner-Lambert Company LLC (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080320-A1 | ANDROGEN RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182132-A1 | 4-oxy-benzonitriles e.g. (1S,4S)-4-(4-Hydroxy-1-methylpentyloxy)-2-trifluoromethylbenzonitrile; acne, alopecia, and oily skin; early puberty, premenstrual syndrome, lung cancer, osteoporosis, hypogonadism, age-related muscle mass decline, hormone-dependent cancer | HU LAIN-YEN (US) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182132-A1 | 4-oxy-benzonitriles e.g. (1S,4S)-4-(4-Hydroxy-1-methylpentyloxy)-2-trifluoromethylbenzonitrile; acne, alopecia, and oily skin; early puberty, premenstrual syndrome, lung cancer, osteoporosis, hypogonadism, age-related muscle mass decline, hormone-dependent cancer | NR5A1, AR, SHBG | AR 2/4885PGR 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.